Lorenzo Bosisio appointed CEO of EffRx Pharmaceuticals

12 October 2016

Swiss drug developer EffRx Pharmaceuticals today said it has named Lorenzo Bosisio appointed as chief executive effective July 1st, 2016.

Prior to his promotion to CEO, Mr Bosisio served as chief commercial officer since 2013. During his tenure in EffRx, he has built the commercial infrastructure from the ground, successfully launched the company’s lead product, Binosto (alendronate sodium) effervescent tablets, enabling the transformation of EffRx from a drug development company to an integrated biopharmaceutical company with an international footprint.

Mr Bosisio brings significant strategic and operational leadership experience from senior positions at Amgen, Alexion, PwC and Tissot Medical. He has an excellent track record in building new international operations and brands as well as driving transformational growth

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK